GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma
Not Applicable
- Conditions
- melanoma
- Registration Number
- JPRN-jRCT2080221174
- Lead Sponsor
- GlaxoSmithKline K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Refer to 'GSK Clinical Study Register'
Exclusion Criteria
Refer to 'GSK Clinical Study Register'
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Refer to 'GSK Clinical Study Register'<br>Refer to 'GSK Clinical Study Register'
- Secondary Outcome Measures
Name Time Method Refer to 'GSK Clinical Study Register'<br>Refer to 'GSK Clinical Study Register'